3月18日 - ** 生物技术公司Ovid Therapeutics OVID.O股价盘前上涨约16%至2.33美元
** 称实验性癫痫药物OV329在早期研究中安全性良好
** 服用7毫克剂量的志愿者未报告与治疗相关的副作用；其他事件轻微且持续时间短 - OVID
** 没有出现眼部问题的迹象，而这是同类旧药的已知风险。
** 计划在第二季度对局灶性癫痫发作（一种常见的癫痫形式）进行中期试验
** 还计划对罕见的儿童癫痫发作疾病进行研究，包括结节性硬化综合症和婴儿痉挛症
** 在一轮私人融资中筹集到 6000 万美元，用于支持这些研究
** 2025 年股价上涨约 75%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.